NCT06830512 The Safety and Efficacy Evaluation of Echocardiography-guided Percutaneous Radiofrequency Ablation for Cardiac Tumors: a Single-arm, Prospective, Single-center Clinical Study
| NCT ID | NCT06830512 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Heart Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-01-24 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-01-24 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The safety and efficacy evaluation of echocardiography-guided percutaneous radiofrequency ablation (Liwen prcocedure) for cardiac tumors: a single-arm, prospective, single-center clinical study.
Eligibility Criteria
Inclusion Criteria: 1. Hemodynamic changes caused by cardiac tumors or patients with obvious clinical symptoms such as chest tightness, shortness of breath, palpitations, etc., or the risk of embolization of intracardial tumors; 2. Patients who cannot be completely excised by surgery, cannot tolerate surgery or refuse surgery; 3. The patient was informed of the nature of the clinical study and agreed to participate in all the requirements of the clinical study, signed the informed consent, and agreed to complete the follow-up and follow-up examination required. Exclusion Criteria: 1. Previously documented persistent ventricular tachycardia or ventricular fibrillation, supraventricular tachycardia with hemodynamic disturbance, cardiac arrest, and high atrioventricular block; 2. Previous history of tumor or thromboembolism exfoliating organ embolism; 3. Combined with other heart diseases requiring surgical treatment; 4. Active infections should be treated with antibiotics; 5. Bleeding constitution and coagulation disorders, or anticoagulation, antiplatelet therapy contraindications; 6. Patients who are pregnant, breastfeeding or planning to become pregnant during the clinical study; 7. The disease will cause difficulties in the evaluation of treatment, such as mental illness, metabolic disease, etc.; 8. Patients who cannot tolerate general anesthesia; 9. Severe liver, kidney, lung, brain and other major organ failure; 10. There are no patients who are suitable for the injection path of Liwen operation; 11. Other diseases deemed unsuitable for inclusion by the researchers; 12. The researcher judged that the patients' dependence was poor and could not complete the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06830512 clinical trial?
This trial is open to participants of all sexes, studying Heart Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06830512 currently recruiting?
Yes, NCT06830512 is actively recruiting participants. Contact the research team at liuliwen1969@fmmu.edu.cn for enrollment information.
Where is the NCT06830512 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06830512 clinical trial?
NCT06830512 is sponsored by Xijing Hospital. The trial plans to enroll 40 participants.